Byetta exenatide regulatory update

EMA's CHMP issued a positive opinion to expand the label for Byetta exenatide to include add-on therapy to basal insulin to treat Type II diabetes in patients who have inadequate control on metformin or Actos pioglitazone. Byetta, synthetic exendin-4, is marketed in the U.S. and Europe for Type II diabetes. ...